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Background Since long-term administrations of anti-hyperlipidemic agents result in
reduction in % stenosis or increase in minimum lumen diameter (MLD) of stenotic
coronary segments, it is generally believed that anti-hyperlipidemic agents stabilize vulner-
able coronary plaques. However, recent pathologic and angioscopic studies revealed that
vulnerability of coronary plaques is not related to severity of stenosis and the rims rather
than top of the plaques disrupt, and therefore, angiography is not adequate for evaluation
of vulnerability.
Angioscopy enables macroscopic pathological evaluation of the coronary plaques.
Therefore, we carried out a prospective angioscopic open trial for evaluation of the
stabilizing effects of bezafibrate on coronary plaques.
Methods From April, 1997 to December, 1998, 24 patients underwent coronary
angioscopy of the plaques in the non-targeted vessels during coronary interventions and 6
months later. The patients were divided into control (10 patients, 14 plaques) and beza-
fibrat (14 patients, 21 plaques) groups. Oral administration of bezafibrate (Bezatol SR,
400mg/day) was started immediately after the interventions and was continued for
6 months. The vulnerability score was determined based on angioscopic characteristics of
plaques and it was compared before and 6 months later.
Results Six months later, vulnerability score was reduced (from 1.6 to 0.8; p < 0.05)
in bezafibrate group and unchanged (from 1.4 to 1.3; NS) in control group. In bezafibrate
group, the changes in vulnerability score was not correlated with those in % stenosis or
MLD.
Conclusion The results indicate that bezafibrate can stabilize coronary plaques.
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INTRODUCTION
Since long-term administrations of anti-hyperlipid-
emic agents result in reduction of cardiac events
and increases survival rate, it is generally believed
that anti-hyperlipidemic agents stabilize vulneable
coronary plaques, however without definite
evidence [1-3]. Coronary angiographic follow-up
studies also demonstrated that their beneficial
effects are not necessarily accompanied by signifi-
cant reduction in severity of coronary stenoses
[4-7].
Recent pathologic and angioscopic studies
revealed that vulneability of coronary plaques is
not related to severity of stenoses and the rims
rather than top of the plaques disrupt [8,9]. Also,
angioscopic studies in acute coronary syndromes
demonstrated that plaques in less stenotic portions
disrupt in a certain group of patients [10]. There-
fore, angiography is not adequate for evaluation of
vulnerability.
Angioscopy enables macroscopic pathological
evaluation of the coronary plaques. Therefore, we
carried out a prospective angioscopic open trial for
evaluation of the stabilizing effects of bezafibrate
on coronary plaques in patients who underwent
coronary angioplasty.
SUBJECTS AND METHODS
Angioscopes and their Manipulation
Angioscopes used in this study were 4.7F in
external diameter with an inflatable balloon at the
most tip (Clinical Supply Co, Gifu, Japan). A fiber-
scope (image guide 3000 or 6000 pixels and light
guide 200 pixels) was included in a guiding catheter.
For observation, balloon was inflated with carbon
dioxide and body temperature heparinized (10 U/
ml) saline was infused manually or when necessary
by a power injector at a rate of 2-3 ml/sec. The
fiberscope can be advanced over a 0.014 inch guide
wire for up to 5 cm while the guiding catheter was
fixed. Therefore, coronary luminal changes can be
observed successibly for considerable length during
single observation (Fig. 1).
Subjects
From April, 1997 to December, 1998, 32 patients
were enrolled for coronary angioscopy. The
patients were randomely divided into control and
bezabibrate groups.
Oral administration of bezafibrate (Bezatol SR
Kissei Co, 400rag/day) was started immediately
after the interventions and was continued for 6
months. The plaques in one or two epicardial
arteries not targetted for interventions were obser-
ved during interventions. ix months later, angio-
scopy was repeated for observation of the identical
plaques. Because of experimental nature, informed
consent was obtained from all patients.
Vulnerability Scores
Coronary atherosclerotic plaques are classified in
color, into white, light yellow, white and non-
glistening yellow on mosaic, non-glistening yellow
(rarely brown) and glistening yellow [11,12,13].
Also, they are classified into regular (non-dis-
rupted) and complex (disrupted) plaques [13,14].
Our angioscopic and pathologic studies revealed
that glistening yellow plaques are vulneable and
yellow one the next. Our prospective angioscopic
follow-up study also confirmed that glistening
yellow plaques are vulnerable [10].
Therefore, the vulnerability score of plaques
was determined based on their color and surface
morphology and it was compared before and 6
months later (Table I).
Angiographic Measurement
Percentage stenoses were calibrated using cinean-
giograms and were compared before and 6 months
later. An increase of25% and a decrease of25% in
% stenoses were determined as progression and
regression, respectively, and they were compared
between the control and bezafibrate groups.PLAQUE STABILIZATION 23
FIGURE Angioscope used in this study. Top: fiberscope pulled back. Middle: fiberscope advanced. Bottom: during saline flush.
Plasma Lipids Measurements were measured before initial and repeated
angioscopy and the relationships between anglo-
Plasma total cholesterol (T.Chol), triglyceride scopic changes and those in plasma lipids were
(TG) and high density lipoprotein (HDL) examined.24 Y. UCHIDA et al.
TABLE Angioscopic
plaques
vulnerability score of coronary
A. Plaque color Score
white 0
light yellow
white and yellow
speckled
yellow 2
glistening yellow 3
B. Surface morphology
regular 0
complex
before 6 rn
(A) TH $13
(B) MT $3
Statistical Analysis
All datas were expressed as mean 4- SE and statis-
tical analyses were made using Student’s t test or
x
2 test and p < 0.05 was considered statistically
significant.
(c) KM $6
RESULTS
Angioscopic Changes
Of 32 patients, 14 plaques in 10 control patients
and 21 plaques in 14 patients were successfully
observed during and 6 months after interventions.
No significant differences were observed in
patient’s background between the control and
bezafibrate groups (Table II).
Figure 2 shows representative examples of
the changes in coronary plaques in the treated
group. In Fig. 2A, a glistening yellow complex
(rough surfaced) plaque before was changed
into non-glistening yellow regular plaque (vulner-
ability score from 4 to 2). In Fig. 2B, a non-glisten-
ing yellow regular plaque disappeared almost
completely and the luminal surface became white
(vulnerability score from 2 to 0). In Fig. 2C, a
yellow and brown colored plaque was reduced in
size and the neighbouring surface changed
from light yellow into white (vulnerability score
from 2 to 1). The carina at the bifurcation was
somewhat thickened, indicating fibrotic thicken-
ing. Thus, vulnerability score was reduced (from
FIGURE 2 Changes in coronary plaques before (left) and 6
months after (right) treatment with bezafibrate. (A) a glistening
yellow plaque was changed into yellow. (B) a non-glistening
yellow plaque disappeared (absorbed?). (C) a yellow plaque
was reduced in size and the surrounding portions changed from
light yellow into white in color.
p<O.05
NS
NS p<O.05
0
b a b a
C (n=14) B(n=21)
p<O.01
c
FIGURE 3 Changes in vulneability score, b: before, a: 6
months after. C: control group. B: bezafibrate group. NS: not
significant.
1.6 to 0.8; p < 0.05) in bezafibrate group and was
unchanged (from 1.4 to 1.3; NS) in control group
(Fig. 3).PLAQUE STABILIZATION 25
TABLE II Background
Characteristics Control group (n-- 10) Bezafibrate group (n 14) p value
Age (y.o; means 4- SE) 63.5 4- 2.8 61.2 4- 2.5 NS
Gender (F/M) 0/10 2/12 NS
Angina pectoris 4 9 NS
Acute myocardial infarction 5 2 NS
Old myocardial infarction 3 NS
Coronary riskfactors
hypertension 2 2 NS
current smoker 3 4 NS
hyperlipidemia 3 8 NS
diabetes mellitus 2 4 NS
Medication
antiplatelet drugs (aspirin) 9 14 NS
long acting nitrate 2 4 NS
beta-blockers 3 NS
calcium antagonists 7 10 NS
ACE inhibitors 2 NS
potassium channel openor 6 5 NS
SBP (mmHg) 143.6 4- 5.9 138.6 4- 5.3 NS
DBP (mmHg) 82.6 4- 3.7 83.4 4- 2.4 NS
HR (bpm) 75.4 4- 2.9 71.9 4- 1.8 NS
Plasma lipids
T Chol (mg/dl) 206.5 4- 8.7 222.0 4- 10.8 NS
TG (mg/dl) 140.8 4- 14.4 180.2 4- 21.0 NS
HDL (mg/dl) 41.5 4- 2.8 40.9 4- 2.6 NS
Vessel disease
0 2 NS
6 7 NS
2 2 4 NS
3 NS
Coronary intervention
not performed 2 (2) 3 (3)* NS
POBA 2 (1) 8 (7) NS
STENT 7 (7) 4 (4) NS
*: number of intervention sites (number of patients),
NS: not significant.
<0.05
N
O" 0
b a b a
C (n=14) B(n=21)
C:control B:benzafibrate b:before a:6m after
FIGURE 4 Angiographic changes.
B
In bezafibrate group, % stenosis assessed by
angiography was decreased. However, no signific-
ant differences were observed in progression or
regression assessed by angiography between the
two groups (Fig. 4).
Two or more plaques with vulnerability score
of or more were observed in 4 patients treated.
In 2 of these patients, vulnerability score was
decreased in one plaque but was unchanged in
others (Fig. 5).26 Y. UCHIDA et al.
patient A B C D E F
white
light
yellow or
speckled
yellow
glistening
yellow
O0 0
0 0
0
FIGURE 5 Differential changes in color of regular plaques
(vulnerability score) in the same patients. Open circle: un-
changed. Solid circle: reduced in score.
Changes in Plasma Lipids
The value of T Chol was unchanged and that of
TG was decreased. On the contrary, the value of
HDL was increased in bezafibrate group but were
unchanged in control group (Fig. 6). In bezafibrate
300
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NS FNS
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FIGURE 6 Changes in plasma lipids in control and beza-
fibrat group.
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FIGURE 7 Changes in plasma lipids in stabilized (S) and
unchanged (U) plaque subgroups in bezafibrate group.
group, both T Chol and TG were decreased and
HDL was increased in patients with reduced vul-
nerability score but were unchanged in those with
unchanged score (Fig. 7).
DISCUSSION
The results in this study indicate that 6 month’s
oral administration of bezafibrate reduced vulner-
ability score. In our pathologic study, glistening
yellow plaques had very thin cap covering the
lipid pool. The cap was almost devoid of normal
collagen fibers which act against disruption.
Furthermore, small calcium crystals and ceroids,
intermediate degradets of lipid produced by
macrophages, as well as lipids, were deposited in
the cap. Ex vivo angioscopic studies revealed that
glistening is due to reflection of illumination at
least by small calcium cristals, and existence of
such hard substance in collagen fiber deficient
superficial layer may be easily damaged by
intraluminal pressure or flow changes, spasm, or
distortion by cardiac contraction, resulting in
disruption.
Yellow plaques were classified into lipid pool
and non-lipid pool types. The changes common
to both were superficial depositions of lipid and
abnormal or deficient collagen fibers. Therefore,
we considered that this category of plaques are
more vulnerable than non-atherosclerotic or fibro-
tic plaques which angioscopically exhibit milky or
white color [11,12].
In this study, a glistening yellow plaque was
changed into non-glistening yellow plaques after
6 month’s administration of bezafibrate. Although
fibrotic responses to the mechanical damages
induced by guide wire passing over the plaque
during observation can not be denied, it is likely
that the agent reduced lipid at least in the cap and
the cap became thick due to increased collagen
fibers or extracellar matrix. Non-glistening yellow
plaques were also changed into light yellow or
white, namely vulnerability score was reduced
in the treated group. All these facts suggest thatPLAQUE STABILIZATION 27
vulnerable plaques at least in the segments with
angiographically insignificant stenoses can be
stabilized or regressed by oral administration of
bezafibrate. Because of long term follow-up
study, observation was limited to the plaques in
the segments without significant stenoses. There-
fore, it remains to be elucidated whether those
in significantly stenotic segments are changed
similarly.
Although % stenosis assessed by angiography
was also reduced in the treated group. How-
ever, angiographically determined regression or
progression was not correlated with angioscopic
changes. Therefore, it is beyond angiography for
assessement of plaque stabilization.
Two or more plaques with vulnerability score of
or more could repeatedly be observed in same 4
patients. In 2 of them, one plaque was stabilized
but not in other, suggesting different susceptibility
of plaques to bezafibrate. The reason for this
remains to be elucidated.
In bezafibrate group, TG was reduced and
HDL was increased significantly but T Chol was
unchanged. The treated group was divided into
stabilized (at least one plaque was stabilized) and
unstabilized groups and the changes in plasma
lipids were compared. It was revealed that T Chol
and TG were reduced and HDL was increased
in the former group and none ofthem were changed
in non-stabilized group, suggesting that significant
improvement in plasma lipids is at least neces-
sary for plaque stabilization. However, in indivi-
dual patients, improvement in plasma lipids did
not necessarily mean plaque stabilization, indicat-
ing participation of other unknown factors in
stabilization.
Since angioscopy is an interventional and rather
subjective diagnostic tool, other non-interventional
and more objective tools, including measurement
of plasma factors which selectively reflect vulner-
ability and also non-interventional therapeutic
means should be developed in future to minimize
the great burden of human beings, acute coronary
syndromes.
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